FGF23 and atherosclerosis: In this biomarker substudy of the CANVAS trial among participants with T2DM who were at a high risk of or had established ASCVD, higher circulating FGF-23 was associated with an increased risk of the composite of CV death/HHF and HHF whereas higher circulating hsCRP was associated with an increased risk of CV death and MACE, independent of clinical risk factors, and traditional CV and renal biomarkers.